Last 1,752 GBp
Change Today -18.00 / -1.02%
Volume 64.2K
HIK On Other Exchanges
As of 6:54 AM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

hikma pharmaceuticals plc (HIK) Snapshot

1,753 GBp
Previous Close
1,770 GBp
Day High
1,771 GBp
Day Low
1,751 GBp
52 Week High
07/25/14 - 1,835 GBp
52 Week Low
08/28/13 - 1,001 GBp
Market Cap
Average Volume 10 Days
1.56 GBp
Shares Outstanding
0.22 GBp
Dividend Yield

Related News

No related news articles were found.

hikma pharmaceuticals plc (HIK) Related Businessweek News

View More BusinessWeek News

hikma pharmaceuticals plc (HIK) Details

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms in the Middle East and North Africa, the United States, and Europe. It operates through three segments: Branded, Injectable, and Generic. The Branded segment offers 499 products in 1,256 dosage strengths and forms, which lie in the anti-infective, cardiovascular, central nervous system (CNS), and diabetes therapeutic areas. The Injectables segment markets 200 branded and non-branded products in 379 dosage strengths and forms with a focus on CNS, anti-infective, musculoskeletal, cardiovascular, and oncological therapeutic areas. This segment also offers sterile liquid, powder, lyophilized, and cytotoxic products. The Generics segment provides 11 products in 44 dosage strengths and forms for various therapeutic areas including analgesic, anti-infective, anti-inflammatory, cardiovascular, CNS, respiratory, hormonal, and others. This segment markets its products to chain stores, wholesalers, distributors, health systems, and governmental agencies in the form of tablets, capsules, solutions, and suspensions. In addition, the company offers anesthetics, anti-histamines, gastroenterology and metabolism, dermatology, genitourinary system, transplantation, vitamins and supplements, and miscellaneous products. Further, it manufactures plastic specialized medicinal sterile containers and API; and conducts bio-equivalency studies. The company was founded in 1978 and is based in London, the United Kingdom.

7,067 Employees
Last Reported Date: 03/11/14
Founded in 1978

hikma pharmaceuticals plc (HIK) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $2.4M
Executive Vice Chairman, Chief Executive Offi...
Total Annual Compensation: $1.6M
Compensation as of Fiscal Year 2013.

hikma pharmaceuticals plc (HIK) Key Developments

Hikma Pharmaceuticals plc Declares Interim Dividend and Special Dividend for the First Half Ended June 30, 2014, Payable on 26 September 2014

The board of Hikma Pharmaceuticals plc has declared an interim dividend of 7.0 cents per share (approximately 4.2 pence per share) for the first half ended June 30, 2014, in line with 7.0 cents per share for the first half of 2013. In addition, the board has declared a special dividend of 4.0 cents per share (approximately 2.4 pence per share), reflecting the exceptionally strong performances of the company US businesses in the first half of 2014. The interim and special dividend will be paid on 26 September 2014 to eligible shareholders on the register at the close of business on 29 August 2014. The ex-dividend date is 27 August 2014 and the final date for currency elections is 12 September 2014.

Hikma Pharmaceuticals plc Reports Unaudited Consolidated Earnings Results for the First Half Ended June 30, 2014; Reaffirms Revenue Guidance for Fiscal 2014

Hikma Pharmaceuticals plc reported unaudited consolidated earnings results for the first half ended June 30, 2014. The company reported revenue of $738 million, operating profit of $236 million, profit before tax of $219 million, profit attributable to equity holders of parent of $169 million or 84.5 cents per diluted share against revenue of $638 million, operating profit of $143 million, profit before tax of $111 million, profit attributable to equity holders of parent of $73 million or 36.9 cents per diluted share a year ago. Net cash from operating activities was $200 million against $136 million a year ago. Purchases of property, plant and equipment was $43 million against $27 million a year ago. On an adjusted basis, profit attributable to shareholders rose 44% to $176 million. Group  revenue increased by 16% to $738 million, driven by the very strong performance of Injectables business in the first half. On an adjusted basis, Group operating profit increased by $56 million, or 30%, to $245 million. Group net debt decreased from $267 million at 31 December 2013 to $175 million at 30 June 2014. Group revenue increased by 16% to $738 million, driven by the strong performance of the Injectables business. The company continues to expect the group to deliver full year revenue growth of around 5% in 2014.

Hikma Pharmaceuticals plc, H1 2014 Earnings Call, Aug 20, 2014

Hikma Pharmaceuticals plc, H1 2014 Earnings Call, Aug 20, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HIK:LN 1,752.00 GBp -18.00

HIK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $39.02 USD +0.59
BTG PLC 660.00 GBp +7.50
Richter Gedeon Nyrt 3,900 -15.00
Endo International PLC $65.23 USD +0.34
Stada Arzneimittel AG €30.74 EUR +0.305
View Industry Companies

Industry Analysis


Industry Average

Valuation HIK Industry Range
Price/Earnings 18.7x
Price/Sales 3.9x
Price/Book 5.0x
Price/Cash Flow 18.6x
TEV/Sales 3.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HIKMA PHARMACEUTICALS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at